Fosciclopirox

CAS No. 1380539-06-9

Fosciclopirox( CPX-POM )

Catalog No. M28675 CAS No. 1380539-06-9

Fosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following parenteral administration.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 50 In Stock
2MG 29 In Stock
5MG 46 In Stock
10MG 79 In Stock
25MG 164 In Stock
50MG 254 In Stock
100MG 375 In Stock
200MG 533 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Fosciclopirox
  • Note
    Research use only, not for human use.
  • Brief Description
    Fosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following parenteral administration.
  • Description
    Fosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following parenteral administration.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CPX-POM
  • Pathway
    Neuroscience
  • Target
    Gamma-secretase
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1380539-06-9
  • Formula Weight
    317.278
  • Molecular Formula
    C13H20NO6P
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (315.19 mM)
  • SMILES
    Cc1cc(C2CCCCC2)n(OCOP(O)(O)=O)c(=O)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Faria DB, et al. Effects of lidocaine and droxicainide on myocardial necrosis: a comparative study. J Am Coll Cardiol. 1983 Jun;1(6):1447-52.
molnova catalog
related products
  • CB-103

    CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity. CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines, and?exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.

  • Aβ42-IN-2

    Aβ42-IN-2, a γ-secretase modulator with an IC50 of 6.5 nM for Αβ42, can be used for Alzheimer's disease research .

  • YO-01027

    YO-01027 (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM for APPL and Notch cleavage, respectively.